Skip to main content

NextPharma to Manufacture Epigenomics' Colon Cancer Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – NextPharma will manufacture Epigenomics' colon cancer test for certain markets worldwide, the firms announced today.

Under terms of the deal, NextPharma will manufacture Epigenomics' Epi proColon test kit in Europe and other markets and will manufacture a cGMP-compliant version of the test, which is currently under development, for the US market.

The test, which identifies the presence of methylated DNA of the Septin9 gene, is CE-marked in Europe. Berlin, Germany-based Epigenomics plans to file for US marketing clearance of the test next year.

Surrey, UK-based NextPharma will manufacture the Epi proColon test at its facilities in San Diego, which are ISO 13485 certified for manufacturing medical devices.

"In NextPharma we have found the ideal contract manufacturing partner to satisfy the increasing demand for our Epi proColon test kit in Europe," Uwe Staub, SVP of product development for Epigenomics, said in a statement.

Financial and other terms of the agreement were not disclosed.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.